BR0007754A - hydroxamide acid, process to prepare the same, compound, method of inhibiting pathological changes mediated by the enzyme that converts atnf-alpha (tage) in mammal in need of it, and pharmaceutical composition - Google Patents

hydroxamide acid, process to prepare the same, compound, method of inhibiting pathological changes mediated by the enzyme that converts atnf-alpha (tage) in mammal in need of it, and pharmaceutical composition

Info

Publication number
BR0007754A
BR0007754A BR0007754-2A BR0007754A BR0007754A BR 0007754 A BR0007754 A BR 0007754A BR 0007754 A BR0007754 A BR 0007754A BR 0007754 A BR0007754 A BR 0007754A
Authority
BR
Brazil
Prior art keywords
enzyme
converts
compound
need
pathological changes
Prior art date
Application number
BR0007754-2A
Other languages
Portuguese (pt)
Inventor
Jeremy Ian Levin
James Ming Chen
Arie Zask
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of BR0007754A publication Critical patent/BR0007754A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/78—Halides of sulfonic acids
    • C07C309/86—Halides of sulfonic acids having halosulfonyl groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/87—Halides of sulfonic acids having halosulfonyl groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing singly-bound oxygen atoms bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/41—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing singly-bound oxygen atoms bound to the carbon skeleton
    • C07C309/42—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing singly-bound oxygen atoms bound to the carbon skeleton having the sulfo groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

"áCIDOS DE HIDROXAMIDA, PROCESSO PARA PREPARAROS MESMOS, COMPOSTO, MéTODO DE INIBIR MUDANçASPATOLóGICAS MEDIADAS PELA ENZIMA QUE CONVERTE ATNFalfa (TACE) EM UM MAMìFERO EM NECESSIDADE DESTE,E, COMPOSIçãO FARMACêUTICA". A invenção divulga ácidosde hidroxamida da fórmula (B): que são utilizáveis no tratamento decondições de doença mediadas pela TNF-<244>, tais como artritereumatóide, osteoartrite, sépsia, AIDS, colite ulcerativa, esclerosemúltipla, doença de Crohn e perda degenerativa de cartilagem. Nafórmula acima, a linha pontilhada representa uma ligação duplaopcional, e R~ 5~, R~ 6~, R~ 7~, R~ 8~, R~ 11~, R~ 12~, X, Ye Z têm os significados dados no relatório descritivo."HYDROXAMID ACIDS, PROCESS TO PREPARE THEMSELVES, COMPOUND, METHOD OF INHIBITING PATHOLOGICAL CHANGES MEASURED BY ENZYME THAT CONVERTS ATNPHALPH (TACE) IN A MAMMALIAN IN NEED OF THIS, AND, COMPOSITION" PHARMACEUTICAL. The invention discloses hydroxamide acids of formula (B): which are usable in the treatment of disease conditions mediated by TNF- <244>, such as arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss . In the above formula, the dotted line represents an optional double bond, and R ~ 5 ~, R ~ 6 ~, R ~ 7 ~, R ~ 8 ~, R ~ 11 ~, R ~ 12 ~, X, Y and Z have the meanings given in the specification.

BR0007754-2A 1999-01-27 2000-01-27 hydroxamide acid, process to prepare the same, compound, method of inhibiting pathological changes mediated by the enzyme that converts atnf-alpha (tage) in mammal in need of it, and pharmaceutical composition BR0007754A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23908399A 1999-01-27 1999-01-27
PCT/US2000/001865 WO2000044711A1 (en) 1999-01-27 2000-01-27 ACETYLENIC $G(b)-SULFONAMIDO AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS

Publications (1)

Publication Number Publication Date
BR0007754A true BR0007754A (en) 2001-11-13

Family

ID=22900530

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0007754-2A BR0007754A (en) 1999-01-27 2000-01-27 hydroxamide acid, process to prepare the same, compound, method of inhibiting pathological changes mediated by the enzyme that converts atnf-alpha (tage) in mammal in need of it, and pharmaceutical composition

Country Status (16)

Country Link
EP (1) EP1147078A1 (en)
JP (1) JP2002535383A (en)
KR (1) KR20010089617A (en)
CN (1) CN1337944A (en)
AR (1) AR035478A1 (en)
AU (1) AU769410B2 (en)
BR (1) BR0007754A (en)
CA (1) CA2356345A1 (en)
CZ (1) CZ20012709A3 (en)
EA (1) EA200100808A1 (en)
HU (1) HUP0200605A3 (en)
IL (1) IL144321A0 (en)
NO (1) NO20013639D0 (en)
NZ (1) NZ512025A (en)
WO (1) WO2000044711A1 (en)
ZA (1) ZA200104508B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199155B2 (en) 2002-12-23 2007-04-03 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
CN101001834B (en) 2004-03-22 2011-06-29 南方研究院 Nonpeptide inhibitors of matrix metalloproteinases
FR2947268B1 (en) 2009-06-30 2011-08-26 Galderma Res & Dev NOVEL BENZENE-SULFONAMIDE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND THEIR USE IN MEDICINE AND COSMETICS
FR2950057B1 (en) * 2009-09-17 2011-08-26 Galderma Res & Dev NOVEL BENZENE CARBOXYLAMIDE COMPOUNDS, PROCESS FOR THEIR SYNTHESIS AND THEIR USE IN MEDICINE AND COSMETICS
US20210393632A1 (en) 2018-10-04 2021-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514716A (en) * 1994-02-25 1996-05-07 Sterling Winthrop, Inc. Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
TNSN97084A1 (en) * 1996-05-15 2005-03-15 Bayer Corp BIARYL ACETYLENES AS INHIBITORS OF METALLOPROTEINASE MATRICES
ES2166102T3 (en) * 1996-10-16 2002-04-01 American Cyanamid Co PREPARATION AND USE OF ORTO-SULFONAMIDOARILHYDROXAMIC ACIDS AS INHIBITORS OF MATRIX METALOPROTEINASES AND TACE.
US5977408A (en) * 1996-10-16 1999-11-02 American Cyanamid Company Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
ATE242768T1 (en) * 1997-10-06 2003-06-15 Wyeth Corp PREPARATION AND USE OF ORTHO-SULFONAMIDO BICYCLIC HETEROARYL HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS

Also Published As

Publication number Publication date
CN1337944A (en) 2002-02-27
NO20013639L (en) 2001-07-24
KR20010089617A (en) 2001-10-06
HUP0200605A3 (en) 2005-05-30
NZ512025A (en) 2003-08-29
EP1147078A1 (en) 2001-10-24
AU769410B2 (en) 2004-01-29
HUP0200605A2 (en) 2002-07-29
IL144321A0 (en) 2002-05-23
EA200100808A1 (en) 2001-12-24
NO20013639D0 (en) 2001-07-24
CZ20012709A3 (en) 2002-04-17
AR035478A1 (en) 2004-06-02
AU2630600A (en) 2000-08-18
WO2000044711A1 (en) 2000-08-03
CA2356345A1 (en) 2000-08-03
ZA200104508B (en) 2002-09-02
JP2002535383A (en) 2002-10-22

Similar Documents

Publication Publication Date Title
BR0007752A (en) Compound, process to prepare the same, method of inhibiting pathological changes mediated by the enzyme that converts tnf- &#34;alpha&#34; (tace) into a mammal in need of it, and pharmaceutical composition
DE69905476T2 (en) PHOSPHONIC ACID DERIVATIVES AS PTP-1B INHIBITORS
ATE417127T1 (en) NUKELIC ACID SEQUENCE DETERMINATION USING ELECTRONIC DETECTION
ATE253545T1 (en) BIARYLACETIC ACID DERIVATIVES AND THEIR USE AS COX-2 INHIBITORS
NO973745L (en) Nucleic acid-containing preparation, its preparation and use
BR0008939A (en) Dimeric compound, pharmaceutical composition, process for the treatment or prophylaxis of, an infection by orthomyxoviruses or paramyxoviruses in a mammal, use of compound and process of detection of influenza virus
DK0769026T4 (en) Fractional polydisperse compositions
EA200100533A1 (en) ERYTHROMYCIN DERIVATIVES, METHOD OF THEIR PRODUCTION AND THEIR APPLICATION AS MEDICINE PRODUCTS
BR0007783A (en) Compound, method of inhibiting pathological changes mediated by the enzyme that converts tnf-a (tace) into a mammal in need of it, pharmaceutical composition, and, processes to prepare a compound
BR0007759A (en) Compound, process for preparing the same, pharmaceutical composition, and methods for treating disease conditions mediated by matrix metalloproteinase in a mammal in need of it, and for treating a patient who is selected from the group that consists of osteoarthritis, rheumatoid arthritis, cartilage loss degenerative and tumor development
BRPI0410861A (en) methods and compositions for the production of amino acids
EA200300062A1 (en) DERIVATIVES OF AMINOALKYLBENZOYL-BENZOFURANE OR BENZOTHIOPHENE, METHOD FOR THEIR PRODUCTION AND CONTAINING THEIR COMPOSITIONS
DE602005020185D1 (en) PROCESS FOR PREPARATION OF 17-HYDROXY-6 BETA, 7 BETA, 15 BETA, 16 BETA-BISMETHYLENE-17ALPHA-PREGN-4HEN PRODUCTS FOR THIS PROCESS
BR9408392A (en) Derivatives of arylacetic acids and their use as fungicides
ATE209187T1 (en) FLUORINATED 2-NITROIMIDAZOLE ANALOGUE FOR THE DETECTION OF HYPOXIC TUMOR CELLS
BR9710911A (en) A process for forming a peracid and a composition comprising said peracid.
BR0007754A (en) hydroxamide acid, process to prepare the same, compound, method of inhibiting pathological changes mediated by the enzyme that converts atnf-alpha (tage) in mammal in need of it, and pharmaceutical composition
BR0007727A (en) Compound, process to prepare the compounds, method to inhibit pathological changes mediated by the enzyme that converts tnf-alpha (tace) into a mammal in need of it, and pharmaceutical composition
EA200300066A1 (en) DERIVATIVES OF AMINOALCOXIBENZYL-BENZOFURANE OR BENZOTHIOPHENE, METHOD FOR THEIR PRODUCTION AND THEIR COMPOSITIONS
BR0308601A (en) plasma carboxypeptidase b inhibitors
AR011126A1 (en) PROCEDURE FOR PREPARING EPROSARTANE AND INTERMEDIATE COMPOUNDS.
BR0007750A (en) Compound, process to prepare the same, method to inhibit pathological changes mediated by the enzyme that converts tnfalfa (tace) into a mammal in need of it, and pharmaceutical composition
HUP0202733A2 (en) Intermediates for the production of naphthyridine-3-carboxylic acid derivatives
BR0007760A (en) Compound, process to prepare the same, method to inhibit pathological changes mediated by the enzyme that converts tnf-alpha (tace) into a mammal in need of it, method to treat a patient suffering from a condition, and pharmaceutical composition
BR0014759A (en) Beta metalloprotease inhibitors disubstituted

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A, 8A E 9A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 NA RPI2003 DE 26/05/2009.